<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html lang="en" xml:lang="en" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
<title>Ministry of Health &amp; Welfare : ABOUT MOHW &gt; Press Release View Content</title>
<link href="../../css/eng/mwf_eng.css" rel="stylesheet" type="text/css"/>
<script src="../../js/jquery-1.11.0.min.js" type="text/javascript"></script>
<script src="../../js/common.js" type="text/javascript"></script>
<script src="../../js/mw_eng.js" type="text/javascript"></script>
<script type="text/javascript">

//<![CDATA[



	// ¸®½ºÆ®·Î ÀÌµ¿

	function jsList()

	{

		var form = document.fmList;

		form.action = "ssg0111ls.jsp";

		form.submit();

	}



	//³»¿ë º¸±â

	function goView(seq)

	{

		var form = document.fmView;

		form.CONT_SEQ.value = seq;

		form.action = "ssg0111vw.jsp";

		form.submit();

	}



	//ÇÏ´Ü ¸®½ºÆ® ÆäÀÌÁö ÀÌµ¿

	function goPage( page)

	{

		var form = document.fmList;

		form.page.value = page;

		form.submit();

	}



	//ÆÄÀÏ ´Ù¿î·Îµå.

	function fileDownLoad(fileSeq)

	{

		if( confirm( "Do you wish to download now?") == true ) {

			var form = document.fmView;

			form.FILE_SEQ.value = fileSeq;

			form.action = "/front_new/modules/download.jsp";

			form.submit();

		}

	}

//]]>

</script>
</head>
<body>
<!-- ¹Ù·Î°¡±â ¸µÅ© -->
<p id="skip-navi">
<a href="#contents">go to the contents</a>
<a href="#snb">go to the menu</a>
</p>
<!-- //¹Ù·Î°¡±â ¸µÅ© -->
<!-- header -->
<div id="wrap">
<!-- head -->
<div class="sbHead" id="head">
<!-- header -->
<div id="header">
<!-- ·Î°í -->
<h1 class="logo"><a href="../261f58801c1da21d0b6f7021b30b648b"><img alt="ministry of health and welfare" src="../../images/eng/common/logo.gif"/></a></h1>
<div class="kor_sym">
<a href="../../../moi.go.kr/eng/sub/a03/nationalSymbol/d5a2e22490af7d4414516807b47a6064" target="_blank" title="new browser"><img alt="National Symbols of the Republic of Korea" src="../../images/eng/common/kor_sym_eng.gif"/></a>
</div>
<!-- function -->
<div class="function">
<!-- [Funciton] - ÆùÆ®»çÀÌÁî -->
<div class="unit">
<div class="ft_size">
<button class="plus" onclick="fontSizeWrap.btnPlus();" type="button"><span class="hide">expand</span></button>
<button class="minus" onclick="fontSizeWrap.btnMinus();" type="button"><span class="hide">reduce</span></button>
<span class="Font_Size"><span class="hide">Font Size</span></span>
</div>
<script type="text/javascript">var fontSizeWrap = new fontSize();</script>
<!-- //[Funciton] - ÆùÆ®»çÀÌÁî -->
<!-- ¾ð¾îº° ¸µÅ© -->
<ul class="global_language">
<li class="mobile"><a href="../../m_eng/50b06ecdc2a14f90913d780c3460fca4" target="_blank" title="new browser"><span class="hide">Mobile</span></a></li>
<li class="Korean"><a href="../../front_new/647a6a76a15a5a8bfc6d5f73d0d9d4d1" target="_blank" title="new browser"><span class="hide">Korean</span></a></li>
<li class="sitemap"><a href="../cs/38f03257ef34df8e601ed2e794b4f84f"><span class="hide">sitemap</span></a></li>
<li class="a-z"><a href="../cs/1001c96bb6754f09ed925f7b6d593bf7"><span class="hide">A-Z Index</span></a></li>
</ul>
<!-- //¾ð¾îº° ¸µÅ© -->
<!-- ¸Þ´º¼³Á¤ -->
<div class="mnsetup">
<div class="btnsetup"><a class="btnms" href="#msetup_layer" id="svcmore_h"><span class="hide">my menu</span></a></div>
<div class="msetup_layer" id="msetup_layer">
<h2>
<img alt="Menu setup" src="../../images/eng/main/musetup.gif"/>
</h2>
<div class="mnsetup_cont">
<ul class="list" id="fmenu"><li>My menu list</li></ul>
</div>
<div class="cg_contwrap">
<div class="cg_cont">
<!-- ÀüÃ¼¸ñ·Ï -->
<ul class="ms_category">
<li>
<input class="input-check" id="mw_100103" name="setmenu" type="checkbox" value="/eng/sg/ssg0103mn.jsp?PAR_MENU_ID=1001&amp;MENU_ID=100103|100103|Organization"/>
<label for="mw_100103">Organization</label>
</li>
<li>
<input class="input-check" id="mw_100113" name="setmenu" type="checkbox" value="/eng/sg/ssg0101mn.jsp?PAR_MENU_ID=1001&amp;MENU_ID=100113|100113|Contact Us"/>
<label for="mw_100113">Contact Us</label>
</li>
<li>
<input class="input-check" id="mw_100105" name="setmenu" type="checkbox" value="/eng/sg/ssg0105mn.jsp?PAR_MENU_ID=1001&amp;MENU_ID=100105|100105|Minister's Profile"/>
<label for="mw_100105">Minister's Profile</label>
</li>
<li>
<input class="input-check" id="mw_100111" name="setmenu" type="checkbox" value="/eng/sg/ssg0111ls.jsp?PAR_MENU_ID=1001&amp;MENU_ID=100111|100111|Press Release"/>
<label for="mw_100111">Press Release</label>
</li>
<li>
<input class="input-check" id="mw_10031801" name="setmenu" type="checkbox" value="/eng/jc/sjc0101mn.jsp?PAR_MENU_ID=1003&amp;MENU_ID=10031801|10031801|Policies"/>
<label for="mw_10031801">Policies</label>
</li>
<li>
<input class="input-check" id="mw_100408" name="setmenu" type="checkbox" value="/eng/cs/scs0301mn.jsp?PAR_MENU_ID=1004&amp;MENU_ID=100408|100408|RSS"/>
<label for="mw_100408">RSS</label>
</li>
<li>
<input class="input-check" id="mw_100410" name="setmenu" type="checkbox" value="/eng/cs/scs0301mn.jsp?PAR_MENU_ID=1004&amp;MENU_ID=100410|100410|Privacy Guideline"/>
<label for="mw_100410">Privacy Guideline</label>
</li>
<li>
<input class="input-check" id="mw_100404" name="setmenu" type="checkbox" value="/eng/cs/scs0301mn.jsp?PAR_MENU_ID=1004&amp;MENU_ID=100404|100404|Users Guide"/>
<label for="mw_100404">Users Guide</label>
</li>
</ul>
<!-- //ÀüÃ¼¸ñ·Ï -->
</div>
<!-- ¹öÆ° Á¤·Ä -->
<div class="btn_msetup">
<p class="left"><input alt="default" class="input-image" id="mymenu_default" src="/images/eng/btn/btn_base.gif" type="image"/></p>
<span class="cg_msg">User can personalize the website</span>
<p class="center">
<input alt="confirm" class="input-image" id="mymenu_set" src="/images/eng/btn/btn_confirm.gif" type="image"/>
<!--a href="#" id="mymenu_set" ><img src="/images/front/btn/btn_confirm.gif" alt="È®ÀÎ" /></a-->
<input alt="cancel" class="input-image" id="mymenu_cancel" src="/images/eng/btn/btn_cancel.gif" type="image"/>
</p>
<p class="right"><a href="../cs/38f03257ef34df8e601ed2e794b4f84f">sitemap</a></p>
</div>
<!-- //¹öÆ° Á¤·Ä -->
</div>
<p class="btn-more"><button class="msbtn_close" id="msbtn_close" type="button"><span class="hide">close</span></button></p>
</div>
</div>
<!-- //¸Þ´º¼³Á¤ -->
<!-- °Ë»ö -->
<!-- 

					<div class="search">

						<form method="post" name="fmSearch" action="/eng/cs/scs0401ls.jsp" onsubmit="return searchCommon(this)" >

							<input type="hidden" name="PAR_MENU_ID" value="1004" />

							<input type="hidden" name="MENU_ID" value="100406" />

							<input type="hidden" name="SEARCHKEY" value="TITLE" />				

							<fieldset>

								<legend>search</legend>

								<label for="SEARCHVALUE" class="hide">search value</label>

								<input type="text" id="SEARCHVALUE" name="SEARCHVALUE" class="input-text" />

								<input type="image" class="input-image" src="/images/eng/common/tl_btnsearch.gif" alt="search" />

							</fieldset>

						</form>

					</div>

					 -->
<!-- //°Ë»ö -->
</div><!-- //unit -->
</div>
<!-- //function -->
</div>
<!-- //header -->
</div>
<!-- //head -->
<hr/>
<!-- spot main -->
<div id="spot-sub">
<img alt="A life-long friend who stands by the public" src="../../images/front_eng/sg/img_head_sg.jpg"/>
</div>
<!-- //spot main -->
<hr/>
<!-- container -->
<div class="clear" id="container">
<div id="subwrap">
<!-- snb -->
<div id="snb">
<h2><a href="616feca8de871f8a1f1e040342b5d550"><img alt="About MW" src="../../images/front_eng/title/h2_am.gif"/></a></h2>
<ul id="snbMenu1">
<li><a href="616feca8de871f8a1f1e040342b5d550"><img alt="Vision &amp; Mission" src="../../images/front_eng/title/left_am01.gif"/></a>
</li>
<li><a href="93dae7d73a99735630654fc2fb46a9eb"><img alt="Organization" src="../../images/front_eng/title/left_am02.gif"/></a>
</li>
<li><a href="482124899dc6a43227599ea28a921fea"><img alt="Contact Us" src="../../images/front_eng/title/left_am03.gif"/></a>
</li>
<li><a href="2d75b746f82cbae41316bd3da4ceb30d"><img alt="Minister¡¯s Profile" src="../../images/front_eng/title/left_am04.gif"/></a>
</li>
<li><a href="a2fde158a68020769e116fe2815d95aa"><img alt="Vice Minister¡¯s Profile" src="../../images/front_eng/title/left_am05.gif"/></a>
</li>
<li><a href="8c6914a853d28a0cf2ce417c6d5fe3ce"><img alt="Past Ministers &amp; Vice Ministers" src="../../images/front_eng/title/left_am06.gif"/></a>
</li>
<li><a href="a79fdae6ffae612a0b5f784645afb1db"><img alt="Location" src="../../images/front_eng/title/left_am07.gif"/></a>
</li>
<li class="on"><a href="76b19fd6a92fcb216e55a4e9dea9a4c8"><img alt="Press Release" src="../../images/front_eng/title/left_am08_over.gif"/></a>
</li>
<li><a href="ea8a1ea6f8dcdcb2b03b8ebc89df5ef6"><img alt="129 Call Center" src="../../images/front_eng/title/left_am09.gif"/></a>
</li>
<li><a href="../../../www.epeople.go.kr/jsp/user/on/eng/ebb342dee28c17242d927d0b1019800f" target="_blank"><img alt="Online Petition" src="../../images/front_eng/title/left_am10.gif"/></a>
</li>
</ul>
<h2><a href="../jc/f397eab66fb162470b191bcc18dfac4f"><img alt="Policies" src="../../images/front_eng/title/h2_pl.gif"/></a></h2>
<ul id="snbMenu2">
<li class="submenu"><img alt="Enhancement of Customized Welfare Services by Life-Cycle Phase" src="../../images/front_new/title/left_pl100321.gif"/>
<ul>
<li><a href="../jc/f397eab66fb162470b191bcc18dfac4f"><img alt="Reinforcement of support for income growth and work opportunities of low-income people" src="../../images/front_new/title/left_pl10032101.gif"/></a></li>
<li><a href="../jc/6d963af417c35f2c3575a2f47d93315d"><img alt="Welfare services reaching out to people and improvement of public perception" src="../../images/front_new/title/left_pl10032102.gif"/></a></li>
<li><a href="../jc/7c117d987132de318dd869c7e15cd6d1"><img alt="Promotion of rights and interests of children, the disabled, the elderly, etc." src="../../images/front_new/title/left_pl10032103.gif"/></a></li>
<li><a href="../jc/3cd7dc5b01d534d90eba055e35cdf386"><img alt="Reduction of burden of medical expenses, and the reorganization of the system for determining health insurance premiums" src="../../images/front_new/title/left_pl10032104.gif"/></a></li>
</ul>
</li>
<li class="submenu"><img alt="Establishment of Health Insurance System centered on People" src="../../images/front_new/title/left_pl100322.gif"/>
<ul>
<li><a href="../jc/6698fa46cb8d35f0f8aeb6f289ab2ce9"><img alt="Reinforcement of patient-oriented medical services" src="../../images/front_new/title/left_pl10032201.gif"/></a></li>
<li><a href="../jc/6194a5e0555dab84754814c541f09b27"><img alt="Strengthening of essential and public health care services and systematic response to infectious diseases" src="../../images/front_new/title/left_pl10032202.gif"/></a></li>
<li><a href="../jc/7603054a50c83c708da6d6702afe3d14"><img alt="Reinforcement of Preventive Health Care" src="../../images/front_new/title/left_pl10032203.gif"/></a></li>
<li><a href="../jc/5975190b9def38149afd3ad48132162f"><img alt="Enhancement of healthcare industry performance and job creation" src="../../images/front_new/title/left_pl10032204.gif"/></a></li>
</ul>
</li>
<li class="submenu"><img alt="Strengthening Responses to Demographic Crisis" src="../../images/front_new/title/left_pl100323.gif"/>
<ul>
<li><a href="../jc/8334fe91b7312eb840b99581e90bc297"><img alt="Establishment of a response system for coping with low birthrate" src="../../images/front_new/title/left_pl10032301.gif"/></a></li>
<li><a href="../jc/687f9bcd11741aea5264c8392dc17ffc"><img alt="Improvement of a system for supporting childbirth and parenting" src="../../images/front_new/title/left_pl10032302.gif"/></a></li>
<li><a href="../jc/d59e41ec8156d3ed1193b5f64629cf85"><img alt="Enhancement of preparation for aging society" src="../../images/front_new/title/left_pl10032303.gif"/></a></li>
</ul>
</li>
</ul>
<h2><a href="../cs/b64cc4894874ba0eb4af154d245908a9"><img alt="Help" src="../../images/front_eng/title/h2_hp.gif"/></a></h2>
<ul id="snbMenu3">
<li><a href="../cs/b64cc4894874ba0eb4af154d245908a9"><img alt="Users Guide" src="../../images/front_eng/title/left_hp01.gif"/></a>
</li>
<li><a href="../cs/81e6dbd0ed113665170a29b899ab0c21"><img alt="Privacy Guideline" src="../../images/front_eng/title/left_hp04.gif"/></a>
</li>
<li><a href="../cs/bab2f9d80d5980695b6081cb22ceb64b"><img alt="RSS" src="../../images/front_eng/title/left_hp03.gif"/></a>
</li>
<li><a href="../cs/38f03257ef34df8e601ed2e794b4f84f"><img alt="Sitemap" src="../../images/front_eng/title/left_hp05.gif"/></a>
</li>
<li><a href="../cs/1001c96bb6754f09ed925f7b6d593bf7"><img alt="A-Z Index" src="../../images/front_eng/title/left_hp06.gif"/></a>
</li>
</ul>
</div>
<script src="../../js/jquery-1.11.0.min.js" type="text/javascript"></script>
<script type="text/javascript">
			$('.submenu').last().find('ul').attr('class', 'noline');
			imgMenuOver("snb");
			
			$(function(){
				$(".on").parents('ul').slideDown();
			});	
			
			$(".submenu").click(function(){
				$(".submenu").not($(this)).children('ul').slideUp();
				$(this).children('ul').slideToggle();
			});
		</script>
<!-- //snb -->
<!-- contents -->
<div id="contents">
<!-- mnvisual - ÄÁÅÙÃ÷ Å¸ÀÌÆ² -->
<div class="mnvisual">
<!-- h2 - Å¸ÀÌÆ² -->
<!-- //h2 - Å¸ÀÌÆ² -->
<!-- location - ÁÖ¼Ò -->
<div id="location"> <a class="home" href="../261f58801c1da21d0b6f7021b30b648b">HOME</a> &gt; <a href="616feca8de871f8a1f1e040342b5d550">ABOUT MOHW</a> &gt; <span class="here">Press Release</span></div>
<!-- //location - ÁÖ¼Ò -->
</div>
<!-- //mnvisual - ÄÁÅÙÃ÷ Å¸ÀÌÆ² -->
<!-- content-area -->
<div class="content-area">
<!-- DB ¿¡¼­ contents µ¥ÀÌÅÍ¸¦ °¡Á®¿Í¼­ »Ñ·ÁÁØ´Ù. -->
<!-- board -->
<form action="ssg0111vw.jsp" method="post" name="fmView">
<input name="PAR_MENU_ID" type="hidden" value="1001"/>
<input name="MENU_ID" type="hidden" value="100111"/>
<input name="page" type="hidden" value="18"/>
<input name="CONT_SEQ" type="hidden" value="270752"/>
<input name="MENU_ID" type="hidden" value="100111"/>
<input name="FILE_SEQ" type="hidden" value=""/>
<input name="SEARCHKEY" type="hidden" value=""/>
<input name="SEARCHVALUE" type="hidden" value=""/>
<!-- table:view -->
<table class="view" summary="ABOUT MOHW &gt; Press Release detail.">
<caption>ABOUT MOHW &gt; Press Release</caption>
<colgroup>
<col width="12%"/><col width="38%"/><col width="12%"/><col width="38%"/>
</colgroup>
<tbody>
<tr>
<th scope="row">Subject</th>
<td colspan="3">National R&amp;D investment has begun in earnest in stell cell and regeneration medicine to overcome rare and incurable diseases</td>
</tr>
<tr>
<th scope="row">Date</th>
<td>2012-04-20</td>
<th scope="row">Hit</th>
<td>4545</td>
</tr>
<tr>
<th scope="row">Contents</th>
<td class="view" colspan="3"><p align="center" class="MsoNormal" style="text-align: center; line-height: 120%; margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all">
<b><u><span lang="EN-US" style="line-height: 120%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.5pt; color: black; font-size: 16pt; mso-font-kerning: 0pt; mso-fareast-font-family: hyÇìµå¶óÀÎm">National R&amp;D investment has begun in earnest in stell cell and regeneration medicine to overcome rare and incurable diseases<o:p></o:p></span></u></b></p>
<p align="center" class="MsoNormal" style="text-align: center; line-height: 120%; margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all">
<u><span lang="EN-US" style="line-height: 120%; font-family: 'arial', 'sans-serif'; color: black; font-size: 16pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><span style="text-decoration: none"> </span></o:p></span></u></p>
<p align="center" class="MsoNormal" style="text-align: center; line-height: 140%; margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all">
<font size="2"><font color="#000000"><span lang="EN-US" style="font-family: 'arial', 'sans-serif'">- Finalization of ‘2012 stem cell/regeneration medicine R&amp;D implementation plan’ and the contest for research and development program</span><b><span lang="EN-US" style="line-height: 140%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.9pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ"> -</span></b></font><span lang="EN-US" style="line-height: 140%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p align="center" class="MsoNormal" style="text-align: center; line-height: 150%; margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all">
<font size="2"><font color="#000000"><span lang="EN-US" style="font-family: 'arial', 'sans-serif'">-33.0 billion won investment in total in R&amp;D for development of stem cell cure 2012 -</span><b><span lang="EN-US" style="line-height: 150%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.7pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">-</span></b></font><span lang="EN-US" style="line-height: 150%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p align="center" class="MsoNormal" style="text-align: center; line-height: 150%; margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all">
<font size="2"><b><span lang="EN-US" style="line-height: 150%; font-family: 'arial', 'sans-serif'; letter-spacing: -1.7pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">- </span></b><font color="#000000"><span lang="EN-US" style="font-family: 'arial', 'sans-serif'">The investment that has remained at the level of supporting the basic research so far will be expanded to R&amp;D area for commercialization. </span><span lang="EN-US" style="line-height: 150%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></font></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -22.7pt; margin: 0cm 0cm 0pt 22.7pt; vertical-align: baseline">
<span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p align="center" class="MsoNormal" style="text-align: center; line-height: 130%; text-indent: -31.4pt; margin: 0cm 0cm 0pt 31.4pt; vertical-align: baseline; word-break: keep-all">
<span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -25.3pt; margin: 0cm 0cm 0pt 25.3pt; vertical-align: baseline">
<font size="2"><b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">¡à Ministry of Health and Welfare </span></b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">(Minister Rim, Chae Min) announced that it would invest 33.0 billion won, four times greater than the amount of investment made in 2011 (8.7 billion won) as the R&amp;D budget for stem cell/regeneration medicine in order to develop new treatment in rare and incurable disease early and make Korea leap forward into a global power in the area of stem cell industry..</span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -31.4pt; margin: 0cm 0cm 0pt 31.4pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 10pt">
<font size="2"><font color="#000000"><span lang="EN-US" style="font-family: 'arial', 'sans-serif'">*45.9 billion won when the budgets of KCDC (operation of stem cell bank, etc), and KFDA (safety management, etc ) included.</span><span lang="EN-US" style="font-family: 'arial', 'sans-serif'; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></font></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -31.4pt; margin: 0cm 0cm 0pt 31.4pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ"><font size="2">** the government budget (6 ministries/agencies) related to stem cell in 2012: 100.4 billion <o:p></o:p></font></span></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -31.4pt; margin: 0cm 0cm 0pt 31.4pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -31.4pt; margin: 0cm 0cm 0pt 31.4pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -30.3pt; margin: 0cm 0cm 0pt 30.3pt; vertical-align: baseline">
<font size="2"><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">¡Û With the expanded investment resources, the government <b style="mso-bidi-font-weight: normal">plans to invest in the commercialization R&amp;D for verification of efficacy and safety of stem cell-based treatment technologies</b>, moving beyond the previous investment area of basic research*. </span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -30.3pt; margin: 0cm 0cm 0pt 30.3pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -31.4pt; margin: 0cm 0cm 0pt 31.4pt; vertical-align: baseline">
<font size="2"><span lang="EN-US" style="font-family: 'arial', 'sans-serif'; letter-spacing: -0.2pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">* Basic/source research regarding the control of physiological functions of stem cells and the identification of stem cell mechanism.<span style="mso-spacerun: yes">  </span></span><span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -31.4pt; margin: 0cm 0cm 0pt 31.4pt; vertical-align: baseline">
<span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -31.4pt; margin: 0cm 0cm 0pt 31.4pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -9pt; margin: 0cm 0cm 0pt 9pt; vertical-align: baseline; mso-char-indent-count: -1.0">
<font size="2"><b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.5pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">¡à Regeneration medical technology</span></b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.5pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">* <span style="mso-bidi-font-weight: bold">using stem cells<b> provides the potential for fundamental treatment of rare/insurable diseases </b>that cannot be cured by current medicine<b>. </b>Thus,<b> the technology is drawing keen attention from the general public and harbors great industrial value as a core future technology. </b></span></span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -22.7pt; margin: 0cm 0cm 0pt 22.7pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 130%; text-indent: -39.5pt; margin: 0cm 0cm 0pt 39.5pt; vertical-align: baseline">
<font size="2"><b><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">* (Regeneration medicine</span></b><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-weight: bold; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">) Technological area to<b> restore certain functions of the human body </b>by treating, replacing or regenerating tissues and organs that were damaged due to aging, disease, accidents and congenital defects.<b> </b></span><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -39.5pt; margin: 0cm 0cm 0pt 39.5pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -36.5pt; margin: 0cm 0cm 0pt 36.5pt; vertical-align: baseline">
<font size="2"><b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">** (Size of global stem cell market)</span></b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ"> $32.4 billion in 2012, growing at 24.2% on yearly average.<span style="mso-spacerun: yes">  </span></span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -36.5pt; margin: 0cm 0cm 0pt 36.5pt; vertical-align: baseline">
<span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -4.4pt; margin: 0cm 0cm 0pt 4.4pt; vertical-align: baseline; mso-char-indent-count: -.5">
<font size="2"><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.6pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">¡Û In particular, Korea’s stem cell/regeneration medicine is <b style="mso-bidi-font-weight: normal">currently in the top ten band</b> worldwide, which gives us rosy <b style="mso-bidi-font-weight: normal">prospects that Korea can be a top global competitor if efficiently supported by the government’s investment</b>.<span style="mso-spacerun: yes">  </span></span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p>
	 </p>
<table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="border-bottom: medium none; border-left: medium none; border-collapse: collapse; border-top: medium none; border-right: medium none; mso-border-alt: solid black .25pt; mso-yfti-tbllook: 1184">
<tbody>
<tr style="height: 187.6pt; mso-yfti-irow: 0; mso-yfti-firstrow: yes; mso-yfti-lastrow: yes">
<td style="border-bottom: black 1pt dotted; border-left: black 1pt dotted; padding-bottom: 1.4pt; background-color: transparent; padding-left: 5.1pt; width: 453.55pt; padding-right: 5.1pt; height: 187.6pt; border-top: black 1pt dotted; border-right: black 1pt dotted; padding-top: 1.4pt; mso-border-alt: dotted black .25pt" width="605">
<p align="center" class="MsoNormal" style="text-align: center; line-height: 160%; text-indent: -31.6pt; margin: 0cm 0cm 0pt 31.6pt; vertical-align: baseline; word-break: keep-all">
<font size="2"><b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">&lt; Korea’s R&amp;D competitiveness in stem cell/regeneration medicine &gt;</span></b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -31.6pt; margin: 0cm 0cm 0pt 31.6pt; vertical-align: baseline">
<font size="2"><span style="line-height: 160%; font-family: 'ms gothic'; color: black; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: 'ms gothic'; mso-font-kerning: 0pt">‣</span><span style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ"> <b style="mso-bidi-font-weight: normal"><span lang="EN-US">3 stem cell therapies obtained approval</span></b><span lang="EN-US"> for the first time in the world. </span></span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: 130%; text-indent: -4.5pt; margin: 0cm 0cm 0pt 4.5pt; vertical-align: baseline; mso-char-indent-count: -.5">
<span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.5pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ"><font size="2">* <b>(Hearticellgram-AMI)</b> </font></span><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; background: white; color: #222222; font-size: 9pt">a stem cell<span class="apple-converted-space"> </span>treatment for<span class="apple-converted-space"> </span></span><em><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; background: white; color: black; font-size: 9pt; mso-bidi-font-weight: bold">acute</span></em><span class="apple-converted-space"><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; background: white; color: #222222; font-size: 9pt"> </span></span><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; background: white; color: #222222; font-size: 9pt">myocardial infarction</span><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.5pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ"><font size="2">/</font></span><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; background: white; color: #222222; font-size: 9pt"> autologous<span class="apple-converted-space"> </span></span><font size="2"><span lang="EN-US" style="line-height: 130%; font-family: wingdings; letter-spacing: -0.5pt; color: black; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: arial; mso-font-kerning: 0pt; mso-ascii-font-family: arial; mso-fareast-font-family: ÇÑ¾çÁß°íµñ; mso-hansi-font-family: arial; mso-char-type: symbol; mso-symbol-font-family: wingdings"><span style="mso-char-type: symbol; mso-symbol-font-family: wingdings"> </span></span><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.5pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">adult stem cells(July 2011), FCB Pharmicell</span><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: 130%; text-indent: -37.5pt; margin: 0cm 0cm 0pt 37.5pt; vertical-align: baseline">
<span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.2pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ"><font size="2">* <b>(Cupistem)</b> a </font></span><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; background: white; color: #222222; font-size: 9pt">treatment for anal fistula in </span><em><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; background: white; color: black; font-size: 9pt; mso-bidi-font-weight: bold">Crohn's</span></em><span class="apple-converted-space"><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; background: white; color: #222222; font-size: 9pt"> </span></span><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; background: white; color: #222222; font-size: 9pt">disease/ using<span class="apple-converted-space"> </span>patients' own stem cells from fatty tissue</span><font size="2"><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.2pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ"> (January 2012), Anterogen</span><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: 130%; text-indent: -37.5pt; margin: 0cm 0cm 0pt 37.5pt; vertical-align: baseline">
<span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.2pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ"><font size="2">* <b>(Cartistem) </b></font></span><span class="apple-converted-space"><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; background: white; color: #222222; font-size: 9pt"> </span></span><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; background: white; color: #222222; font-size: 9pt">a stem cell treatment for damaged<span class="apple-converted-space"> </span></span><em><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; background: white; color: black; font-size: 9pt; mso-bidi-font-weight: bold">cartilage</span></em><font size="2"><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.2pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">/ stem cells taken from same species</span><span lang="EN-US" style="line-height: 130%; font-family: wingdings; letter-spacing: -0.2pt; color: black; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: arial; mso-font-kerning: 0pt; mso-ascii-font-family: arial; mso-fareast-font-family: ÇÑ¾çÁß°íµñ; mso-hansi-font-family: arial; mso-char-type: symbol; mso-symbol-font-family: wingdings"><span style="mso-char-type: symbol; mso-symbol-font-family: wingdings"> </span></span><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.2pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">developed from newborns’ umbilical cord blood (January 2012), MEDIPOST</span><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: 130%; text-indent: -37.5pt; margin: 0cm 0cm 0pt 37.5pt; vertical-align: baseline">
<span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 130%; text-indent: -21pt; margin: 0cm 0cm 0pt 21pt; vertical-align: baseline">
<font size="2"><b><span style="line-height: 130%; font-family: 'ms gothic'; color: black; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: 'ms gothic'; mso-font-kerning: 0pt">‣</span></b><b><span style="line-height: 130%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ"> </span></b><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-weight: bold; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">Korea ranks <b>7<sup>th</sup></b> in terms of paper publication and patent application in the field of regeneration; <b>9<sup>th</sup></b> in terms of the ratio of research in regeneration medicine to the overall bio research; <b>10<sup>th</sup></b> in terms of the quality of research papers. <span style="mso-spacerun: yes"> </span><b><span style="mso-spacerun: yes"> </span></b></span><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: 130%; text-indent: -21pt; margin: 0cm 0cm 0pt 21pt; vertical-align: baseline">
<span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -30.9pt; margin: 0cm 0cm 0pt 30.9pt; vertical-align: baseline">
<font size="2"><span style="line-height: 160%; font-family: 'ms gothic'; color: black; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: 'ms gothic'; mso-font-kerning: 0pt">‣</span><span style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ"> <span lang="EN-US">The number of clinical tests for stem cell therapies is <b style="mso-bidi-font-weight: normal">22 by 7 companies</b>. </span></span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: 130%; text-indent: -30.3pt; margin: 0cm 0cm 0pt 38.6pt; vertical-align: baseline">
<font size="2"><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">* <b style="mso-bidi-font-weight: normal">Clinical tests for human embryonic stem cell therapies were approved</b> for the second time in the world. (November 2010)<span style="mso-spacerun: yes">  </span></span><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
</td>
</tr>
</tbody>
</table>
<p class="MsoNormal" style="line-height: 160%; text-indent: -22.8pt; margin: 0cm 0cm 0pt 22.8pt; vertical-align: baseline">
<span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -22.8pt; margin: 0cm 0cm 0pt 22.8pt; vertical-align: baseline">
<span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -23.3pt; margin: 0cm 0cm 0pt 23.3pt; vertical-align: baseline">
<font size="2"><b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">¡à <span style="letter-spacing: -0.3pt">(Focal areas) The new investment in R&amp;D for commercialization of stem cell/regeneration medicine </span></span></b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.3pt; color: black; mso-bidi-font-weight: bold; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">will be made mainly in the following areas<b>.<span style="mso-spacerun: yes">  </span></b></span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -24.8pt; margin: 0cm 0cm 0pt 24.8pt; vertical-align: baseline">
<span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoListParagraph" style="line-height: 160%; text-indent: -18pt; margin: 0cm 0cm 0pt 38pt; vertical-align: baseline; mso-para-margin-top: 0cm; mso-para-margin-right: 0cm; mso-para-margin-bottom: .0001pt; mso-para-margin-left: 0gd; mso-list: l1 level1 lfo1">
<b style="mso-bidi-font-weight: normal"><span lang="EN-US" style="line-height: 160%; font-family: ±¼¸²; color: black; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><span style="mso-list: ignore"><font size="2">¨ç</font><span style="font: 7pt 'times new roman'">   </span></span></span></b><font size="2"><b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.4pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶"><span style="mso-spacerun: yes"> </span>Areas in which investment is imperative for the sake of public good. </span></b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -33.3pt; margin: 0cm 0cm 0pt 33.3pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -35.5pt; margin: 0cm 0cm 0pt 35.5pt; vertical-align: baseline">
<font size="2"><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">- For <b style="mso-bidi-font-weight: normal">rare diseases</b> which is difficult to expect development treatments by the private sector in a voluntary manner; and for <b style="mso-bidi-font-weight: normal">incurable diseases</b>, i.e. damaged spinal cord, which cause permanent impairment due to the lack of cures at the moment. </span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -35.5pt; margin: 0cm 0cm 0pt 35.5pt; vertical-align: baseline">
<span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoListParagraph" style="line-height: 160%; text-indent: -18pt; margin: 0cm 0cm 0pt 38pt; vertical-align: baseline; mso-para-margin-top: 0cm; mso-para-margin-right: 0cm; mso-para-margin-bottom: .0001pt; mso-para-margin-left: 0gd; mso-list: l1 level1 lfo1">
<b style="mso-bidi-font-weight: normal"><span lang="EN-US" style="line-height: 160%; font-family: ±¼¸²; color: black; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><span style="mso-list: ignore"><font size="2">¨è</font><span style="font: 7pt 'times new roman'">   </span></span></span></b><font size="2"><b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶"><span style="mso-spacerun: yes"> </span>Areas with relatively high technological competitiveness which has the potential to advance into the global market </span></b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -33.3pt; margin: 0cm 0cm 0pt 33.3pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -35.9pt; margin: 0cm 0cm 0pt 35.9pt; vertical-align: baseline">
<font size="2"><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">- <b style="mso-bidi-font-weight: normal">Investment in frequent, chronic diseases</b> such as <b style="mso-bidi-font-weight: normal">arthritis and other musculoskeletal system disorders, diabetes, cardio-cerebrovascular disease, etc.</b> has high industrial value as the market demands the development of various treatments for those diseases. </span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -31.4pt; margin: 0cm 0cm 0pt 31.4pt; vertical-align: baseline">
<span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -23.8pt; margin: 0cm 0cm 0pt 23.8pt; vertical-align: baseline">
<span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -10pt; margin: 0cm 0cm 0pt 10pt; vertical-align: baseline; mso-char-indent-count: -1.0">
<font size="2"><b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">¡à (Core Programs)</span></b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶"> <b style="mso-bidi-font-weight: normal">The following three R&amp;D programs will be implemented with priority under the strategic goal of developing future-oriented cutting-edge stem cell/regeneration technologies and commercializing them at an earlier stage.</b> </span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -23.8pt; margin: 0cm 0cm 0pt 23.8pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoListParagraph" style="line-height: 160%; text-indent: -18pt; margin: 0cm 0cm 0pt 38pt; vertical-align: baseline; mso-para-margin-top: 0cm; mso-para-margin-right: 0cm; mso-para-margin-bottom: .0001pt; mso-para-margin-left: 0gd; mso-list: l0 level1 lfo2">
<b style="mso-bidi-font-weight: normal"><span lang="EN-US" style="line-height: 160%; font-family: ±¼¸²; color: black; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><span style="mso-list: ignore"><font size="2">¨ç</font><span style="font: 7pt 'times new roman'">   </span></span></span></b><font size="2"><b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.9pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶"><span style="mso-spacerun: yes"> </span></span></b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; background: #ffb2b2; letter-spacing: -0.9pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">“Inter-Ministrial Intermediate R&amp;D Program<b>”</b></span><b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.9pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶"> established for better connection between basic and higher-level research</span></b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -31.5pt; margin: 0cm 0cm 0pt 31.5pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -5pt; margin: 0cm 0cm 0pt 5pt; vertical-align: baseline; mso-char-indent-count: -.5">
<font size="2"><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">- Government investment thus far has been characterized by <b style="mso-bidi-font-weight: normal">weak connection between basic research</b> (done by Ministry of Education, Science and Technology) and <b style="mso-bidi-font-weight: normal">intermediate/clinical research</b> (done by Ministry of Health and Welfare), which served as <b style="mso-bidi-font-weight: normal">an impediment for the outcome of basic research to advance towards commercialization</b>. </span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -35.4pt; margin: 0cm 0cm 0pt 35.4pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -35.2pt; margin: 0cm 0cm 0pt 35.2pt; vertical-align: baseline">
<font size="2"><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">- In this regard, the “<b style="mso-bidi-font-weight: normal">Inter-Ministerial Intermediate R&amp;D Program</b>” was set up to facilitate the connection between the <b style="mso-bidi-font-weight: normal">outcome of basic/source research gained in R&amp;D projects conducted by MOEST or others</b> and commercialization efforts.</span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -35.1pt; margin: 0cm 0cm 0pt 35.1pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -53.5pt; margin: 0cm 0cm 0pt 53.5pt; vertical-align: baseline">
<font size="2"><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.7pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">* ‘Core Technology Intermediate Research’: Application can be made on condition that precedent research was conducted. KRW 0.5-1 billion/year, in 3 years.<span style="mso-spacerun: yes">  </span></span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -53.5pt; margin: 0cm 0cm 0pt 53.5pt; vertical-align: baseline">
<span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoListParagraph" style="line-height: 160%; text-indent: -18pt; margin: 0cm 0cm 0pt 38pt; vertical-align: baseline; mso-para-margin-top: 0cm; mso-para-margin-right: 0cm; mso-para-margin-bottom: .0001pt; mso-para-margin-left: 0gd; mso-list: l0 level1 lfo2">
<b style="mso-bidi-font-weight: normal"><span lang="EN-US" style="line-height: 160%; font-family: ±¼¸²; color: black; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><span style="mso-list: ignore"><font size="2">¨è</font><span style="font: 7pt 'times new roman'">   </span></span></span></b><font size="2"><b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.6pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶"><span style="mso-spacerun: yes"> </span><span style="background: #ffb2b2">“Investigator-initiated Clinical Trial Program”</span> expanded to build clinical basis </span></b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -33.3pt; margin: 0cm 0cm 0pt 33.3pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -5pt; margin: 0cm 0cm 0pt 5pt; vertical-align: baseline; mso-char-indent-count: -.5">
<font size="2"><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">- As <b style="mso-bidi-font-weight: normal">stem cell/regeneration medicine is a new arena of technology (or product)</b>, there have been a significant number of cases where approval for clinical trial and commercialization was difficult to achieve due to the <b style="mso-bidi-font-weight: normal">lack of previous clinical research and database</b>. </span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -36.9pt; margin: 0cm 0cm 0pt 36.9pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -35.6pt; margin: 0cm 0cm 0pt 35.6pt; vertical-align: baseline">
<font size="2"><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">- Therefore, <b style="mso-bidi-font-weight: normal">investment budget for “Investigator-initiated Clinical Trial Program” was dramatically expanded</b> to promote creative research by <b style="mso-bidi-font-weight: normal">investigators</b> to facilitate the accumulation of clinical database required for commercialization.<span style="mso-spacerun: yes">  </span></span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -35.4pt; margin: 0cm 0cm 0pt 35.4pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 130%; text-indent: -43.7pt; margin: 0cm 0cm 0pt 43.7pt; vertical-align: baseline">
<font size="2"><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.7pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">* ‘Clinical Research for Basis Building’: KRW 0.3-0.7 billion/year, in 2 years (scheduled to be provided in 2H 2012) <span style="mso-spacerun: yes"> </span></span><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: 130%; text-indent: -43.7pt; margin: 0cm 0cm 0pt 43.7pt; vertical-align: baseline">
<span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoListParagraph" style="line-height: 160%; text-indent: -18pt; margin: 0cm 0cm 0pt 38pt; vertical-align: baseline; mso-para-margin-top: 0cm; mso-para-margin-right: 0cm; mso-para-margin-bottom: .0001pt; mso-para-margin-left: 0gd; mso-list: l0 level1 lfo2">
<b style="mso-bidi-font-weight: normal"><span lang="EN-US" style="line-height: 160%; font-family: ±¼¸²; color: black; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><span style="mso-list: ignore"><font size="2">¨é</font><span style="font: 7pt 'times new roman'">   </span></span></span></b><font size="2"><b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.4pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶"><span style="mso-spacerun: yes"> </span><span style="background: #ffb2b2">“Business-led Consortium Clinical Research Program”</span> through pre-planning competition </span></b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -33.3pt; margin: 0cm 0cm 0pt 33.3pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -36.8pt; margin: 0cm 0cm 0pt 36.8pt; vertical-align: baseline">
<font size="2"><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">- So far, the target of government investment was<b style="mso-bidi-font-weight: normal"> confined mainly to investigators at colleges and universities</b>, <b style="mso-bidi-font-weight: normal">limiting the use of potential research competencies and skills</b> possessed by private companies and hospitals.<span style="mso-spacerun: yes">  </span></span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -35.6pt; margin: 0cm 0cm 0pt 35.6pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -35pt; margin: 0cm 0cm 0pt 35pt; vertical-align: baseline">
<font size="2"><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">- To <b style="mso-bidi-font-weight: normal">realize such research potential</b>, <b style="mso-bidi-font-weight: normal">R&amp;D </b>projects led by venture or pharmaceutical companies <b style="mso-bidi-font-weight: normal">with an aim of commercialization</b> will be pursued in the following approach.</span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -35.1pt; margin: 0cm 0cm 0pt 35.1pt; vertical-align: baseline">
<span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><font size="2"><span style="mso-tab-count: 1">            </span><b style="mso-bidi-font-weight: normal">First</b>, <b style="mso-bidi-font-weight: normal">select subsidy recipients through competition</b> early in the research planning phase. <o:p></o:p></font></span></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -35.1pt; margin: 0cm 0cm 0pt 35.1pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -35.1pt; margin: 0cm 0cm 0pt 35.1pt; vertical-align: baseline">
<span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><font size="2"><span style="mso-tab-count: 1">            </span><b style="mso-bidi-font-weight: normal">Second</b>, <b style="mso-bidi-font-weight: normal">form a business-hospital consortium</b> for higher chance of commercialization. <o:p></o:p></font></span></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -35.1pt; margin: 0cm 0cm 0pt 35.1pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -35.1pt; margin: 0cm 0cm 0pt 35.1pt; vertical-align: baseline">
<font size="2"><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><span style="mso-tab-count: 1">            </span></span><b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">Third,</span></b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶"> <b style="mso-bidi-font-weight: normal">impose royalty fees</b> regarding the outcome of commercialization. <b style="mso-bidi-font-weight: normal">The government reinvests in R&amp;D</b>.</span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -33.3pt; margin: 0cm 0cm 0pt 33.3pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 130%; text-indent: -4.3pt; margin: 0cm 0cm 0pt 4.3pt; vertical-align: baseline; mso-char-indent-count: -.5">
<font size="2"><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.7pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">* </span><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; letter-spacing: -1pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">‘Consortium for Commercialization’: Up to KRW 3 billion/year, in 2-3 years, final selection will be made by evaluating the research plan by phase. </span><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.7pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">(cost for planning will be provided, KRW 30 million, 3 months)</span><span lang="EN-US" style="line-height: 130%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -22.7pt; margin: 0cm 0cm 0pt 22.7pt; vertical-align: baseline">
<span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -22.7pt; margin: 0cm 0cm 0pt 22.7pt; vertical-align: baseline">
<font size="2"><b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.5pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">¡à Ministry of Health and Welfare finalized the “2012 Stem Cell/Regeneration Medicine R&amp;D Implementation Plan” </span></b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.5pt; color: black; mso-bidi-font-weight: bold; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">containing the aforementioned, and opened a contest for R&amp;D projects.<b><span style="mso-spacerun: yes">  </span></b></span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -22.7pt; margin: 0cm 0cm 0pt 22.7pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -22.7pt; margin: 0cm 0cm 0pt 22.7pt; vertical-align: baseline">
<font size="2"><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.1pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">* A</span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.6pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">dvertisement of the contest</span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.1pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ"> can be found on the websites of MOHW or Korea Health Industry Development Institute </span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.6pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">(</span><span lang="EN-US"><a href="../../../C:/Documents and Settings/Owner/My Documents/Downloads/ed7e32cd7189d25b8263110feec0745d"><span style="line-height: 160%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.6pt; color: blue; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">www.mw.go.kr</span></a></span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.6pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">, </span><span lang="EN-US"><a href="../../../C:/Documents and Settings/Owner/My Documents/Downloads/a8cec7235a982b90747e3a85ef64f7fd"><span style="line-height: 160%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.6pt; color: blue; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">www.hpeb.re.kr</span></a></span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; letter-spacing: -0.6pt; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÇÑ¾çÁß°íµñ">).</span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -30.6pt; margin: 0cm 0cm 0pt 30.6pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -5pt; margin: 0cm 0cm 0pt 5pt; vertical-align: baseline; mso-char-indent-count: -.5">
<font size="2"><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">¡Û <b style="mso-bidi-font-weight: normal">To help interested companies and researchers have better understanding</b>, <b style="mso-bidi-font-weight: normal">program presentation will be provided on 13 April, 2:30 pm. in Korean Federation of Science and Technology Societies (KOFST)</b> located in Yeoksam-dong. </span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: normal; text-indent: -31pt; margin: 0cm 0cm 0pt 31pt; vertical-align: baseline">
<span lang="EN-US" style="font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -30pt; margin: 0cm 0cm 0pt 30pt; vertical-align: baseline">
<font size="2"><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">¡Û The presentation will include “<b style="mso-bidi-font-weight: normal">the introduction of MOST stem cell R&amp;D project</b>” (in association with MOST and KFDA) and “<b style="mso-bidi-font-weight: normal">the information about stem cell treatment approvals that researchers and developers should know</b>”.</span><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></font></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -31.4pt; margin: 0cm 0cm 0pt 31.4pt; vertical-align: baseline">
<span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p><font size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="line-height: 160%; text-indent: -23.8pt; margin: 0cm 0cm 0pt 23.8pt; vertical-align: baseline">
<font size="2"><b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">¡à Ministry of Health and Welfare </span></b><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-weight: bold; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ÈÞ¸Õ¸íÁ¶">set out its intention to<b> open up new paths forward for the treatment of rare/incurable diseases by making investment in earnest, and to pave the groundwork for</b> making stem cell/regeneration medicine<b> a high-value added, core growth engine. <span style="mso-spacerun: yes"> </span></b></span></font><a name="_GoBack"></a><span lang="EN-US" style="line-height: 160%; font-family: 'arial', 'sans-serif'; color: black; mso-bidi-font-size: 10.0pt; mso-font-kerning: 0pt; mso-fareast-font-family: ±¼¸²"><o:p></o:p></span></p></td>
</tr>
<tr>
<th scope="row">File</th>
<td colspan="3">
<p><img alt="" src="../../images/common/file/icon_file.gif"/> <a href="../../../download.mohw.go.kr/front_new/modules/114c8dfb43898456f5dbf110a6e77867">[ENG][4.12]_National_RnD_investment_has_begun_in_earnest_in_stell_cell_and_regeneration_medicine_to_overcome_rare_and_incurable_diseases.docx (38 KB / Download : 558)</a></p>
</td>
</tr>
</tbody>
</table>
<!-- /table:view -->
<!-- ÇÏ´Ü ¹öÆ° ¿µ¿ª -->
<div class="btn btm">
<!--  ¿À¸¥ ÂÊ ¿µ¿ª ¹öÆ° -->
<a href="e9a17658ff68b1011b3bf38b014eea17"><img alt="list" class="right" src="../../images/eng/common/btn_list.gif"/></a>
<!--  /¿À¸¥ ÂÊ ¿µ¿ª ¹öÆ° -->
</div>
<!-- /ÇÏ´Ü ¹öÆ° ¿µ¿ª -->
</form>
<br/>
<br/>
<div class="view_list">
<form action="ssg0111ls.jsp" method="post" name="fmList">
<input name="PAR_MENU_ID" type="hidden" value="1001"/>
<input name="MENU_ID" type="hidden" value="100111"/>
<input name="page" type="hidden" value="18"/>
<input name="SEARCHKEY" type="hidden" value=""/>
<input name="SEARCHVALUE" type="hidden" value=""/>
<input name="CONT_SEQ" type="hidden" value=""/>
<!-- table head above list -->
<div id="tablehead">
<p>Total <strong>345</strong> Articles</p>
</div>
<!-- /table head above list -->
<table class="list" summary="Publication list.">
<caption>Publication</caption>
<colgroup>
<col width="8%"/><col width="60%"/>
<col width="16%"/><col width="8%"/><col width="8%"/>
</colgroup>
<thead>
<tr>
<th class="first" scope="col">No</th>
<th scope="col">Subject</th>
<th scope="col">Date</th>
<th scope="col">File</th>
<th scope="col">Hit</th>
</tr>
</thead>
<tbody>
<tr>
<td>175</td>
<td class="left"><a href="fffc2e4a7e7a8e105ad5a72ce1d4377b">MERS Hotline English Service</a></td>
<td>2015-06-12</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>1999</td>
</tr>
<tr>
<td>174</td>
<td class="left"><a href="635775aca590cc59614804018fb57728">87 Hospitals Applied for ‘National Safe Hospital’ ...</a></td>
<td>2015-06-12</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>1256</td>
</tr>
<tr>
<td>173</td>
<td class="left"><a href="02989dd3ea38c93c0dd2206dcbc75036">Press Release Summary (June 11)</a></td>
<td>2015-06-11</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>2263</td>
</tr>
<tr>
<td>172</td>
<td class="left"><a href="943fad1742bd26bf0e0ae85cc5a569b3">Hospitals with Known MERS Exposure (June, 10)</a></td>
<td>2015-06-10</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>2534</td>
</tr>
<tr>
<td>171</td>
<td class="left"><a href="7fa85168c0c9d84989f3aadb63cf2dbb">Press Release Summary (June 10)</a></td>
<td>2015-06-10</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>2040</td>
</tr>
<tr>
<td>170</td>
<td class="left"><a href="872051b888d4ada9229b5116c156c707">MERS Prevention and Reporting Guidance</a></td>
<td>2015-06-10</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>1882</td>
</tr>
<tr>
<td>169</td>
<td class="left"><a href="e15f985f0807e08c9354b6cecb70571d">Must Know about MERS</a></td>
<td>2015-06-10</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>1598</td>
</tr>
<tr>
<td>168</td>
<td class="left"><a href="de7b92b8e948147557678a04d715c756">KOREA-WHO MERS Joint Mission, Messages to Public &amp;...</a></td>
<td>2015-06-10</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>1537</td>
</tr>
<tr>
<td>167</td>
<td class="left"><a href="9e602c5e994ab066595416b2d4da7eac">Press Release Summary</a></td>
<td>2015-06-10</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>1896</td>
</tr>
<tr>
<td>166</td>
<td class="left"><a href="0dce9feba5faf48192fef664540c1e5e">[ENG] [5.20] MERS Case Reported In</a></td>
<td>2015-05-28</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>5014</td>
</tr>
</tbody>
</table>
<!-- /table:list -->
<!-- paging -->
<!-- paging -->
<div id="paging">
<a class="btn" href="ebfb6bc3f850eb20122e1021c6e4c0d1"><img alt="first page" src="../../images/eng/common/btn_firstpage.gif"/></a>
<a class="btn" href="ffdc4366d327476f2a2bdd61bea75d3f"><img alt="pre page" src="../../images/eng/common/btn_prepage.gif"/></a>
<a href="b5ac7ead72941feddd2152cd97408423" title="11page">11</a> 

				<a href="43305223367df6986d635c77763975b3" title="12page">12</a> 

				<a href="2711dbddb6de0a13625580768c3557fa" title="13page">13</a> 

				<a href="291c7b2c06ad0f481977e50fbd85795e" title="14page">14</a> 

				<a href="69279edea38f89c531ee92dcc558f429" title="15page">15</a> 

				<a href="3d5e6982b8cfbd3ae4834a4e77e21144" title="16page">16</a> 

				<a href="32fde42f13158f6b4f430ac227830ad3" title="17page">17</a> 

				<span title="present">18</span> 

				<a href="3fbff7a5c45a170ce3270ba839fff4fb" title="19page">19</a> 

				<a href="095823f82b64fc9c0ab92d552e48e0b3" title="20page">20</a> 

				<a class="btn" href="6c8765ade6af448afd7277d09046c33a"><img alt="next page" src="../../images/eng/common/btn_nextpage.gif"/></a>
<a class="btn" href="2d7e34ab1d5e2a71b1530de73fd24299"><img alt="last page" src="../../images/eng/common/btn_lastpage.gif"/></a>
</div>
<!-- /paging -->
<!-- /paging -->
</form>
<!-- DB ¿¡¼­ contents µ¥ÀÌÅÍ¸¦ °¡Á®¿Í¼­ »Ñ·ÁÁØ´Ù. -->
</div>
</div>
<!-- /contents -->
</div>
</div>
<!-- footer -->
<!-- footer -->
<div id="footer">
<div class="foot">
<p class="flogo"><img alt="ministry of health and welfare" src="../../images/eng/common/flogo.gif"/></p>
<div class="finfo">
<address><img alt="13, Doum 4-ro, Sejong, (30113) Korea ¤ÓCALL CENTER 82-129" src="../../images/eng/common/foot_address.gif"/></address>
<p class="copyright"><img alt="Copyright(C) By MOHW. All rights reserved." src="../../images/eng/common/foot_copyright.gif"/></p>
</div>
<!-- ÀÏÀÏ¹æ¹®ÀÚ¼ö Ãß°¡ -->
<p class="visits">Daily visits : <strong>198</strong></p>
<!--// ÀÏÀÏ¹æ¹®ÀÚ¼ö Ãß°¡ -->
</div>
</div>
<!-- //footer -->
</div>
<div id="returntotop"><a href="#skip-navi">go to the top</a></div>
<script type="text/javascript">
//<![CDATA[
function jsOpenSite(formEl) {	
	var errorMessage = null;
	var objFocus = null;
	if (formEl.sitelink.value.length == 0) {
		errorMessage = "please! select a site to move!";
		objFocus = formEl.sitelink;
	} 
	if(errorMessage != null) {
		alert(errorMessage);
		objFocus.focus();
		return false;
	}
	return true;
}
//]]>	
</script>
<script type="text/javascript">
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-101800795-1', 'auto');
  ga('send', 'pageview');

</script>
<!-- /footer -->
</div>
</body>
</html>